Kwality Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Kwality Pharmaceuticals Ltd is ₹ 1433 as of 06 Apr 15:30 . The P/E Ratio of Kwality Pharmaceuticals Ltd changed from 5 on March 2022 to 3.8 on March 2021 . This represents a CAGR of -5.34% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Kwality Pharmaceuticals Ltd changed from ₹ 601.82 crore on March 2022 to ₹ 58.11 crore on March 2021 . This represents a CAGR of -37.34% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 123.97 crore as compare to the Sep '25 revenue of ₹ 111.95 crore. This represent the growth of 10.74% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Kwality Pharmaceuticals Ltd for the Dec '25 is ₹ 29.65 crore as compare to the Sep '25 ebitda of ₹ 26.25 crore. This represent the growth of 12.95% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Kwality Pharmaceuticals Ltd changed from ₹ 8.35 crore to ₹ 16 crore over 7 quarters. This represents a CAGR of 45.01% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Kwality Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics.
With little background of finished pharmaceuticals and high held spirits and will, he started this business.
He received his first drug license in 1981 approved for liquid oral manufacturing.
Presently, the Company has 56 different sections available at their production centres. Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables.
The Company has the most modern & sophisticated Plant, Equipment, technique, and workforce.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Kwality Pharmaceuticals Ltd or Syncom Formulations (India) Ltd?

Market cap of Kwality Pharmaceuticals Ltd is 1,719 Cr while Market cap of Syncom Formulations (India) Ltd is 1,296 Cr

What are the key factors driving the stock performance of Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

The stock performance of Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

As of May 5, 2026, the Kwality Pharmaceuticals Ltd stock price is INR ₹1657.0. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹13.79.

How do dividend payouts of Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Kwality Pharmaceuticals Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.